secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2026-01-16T23:59:59+00:00
Accession:  0001171843-26-000303
Event type: litigation
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

EPO revokes Arbutus' European patent EP 2279254; company plans appeal
---------------------------------------------------------------------

- EPO Board of Appeal revoked Arbutus' European patent EP 2279254 on Jan 15, 2026; verbal decision without reasons; written decision expected in months.
- Opposition originally filed by Moderna affiliates and Merck in April 2018; two prior EPO decisions had upheld amended patent.
- Company plans to petition EPO Enlarged Board of Appeal upon receipt of written decision; decision affects cases vs Moderna in Switzerland and UPC Case UPC_CFI_191/2025.
- Decision does not impact litigations in US, Japan, Canada, other UPC case (UPC_CFI_192/2025), or cases against Pfizer/BioNTech.
- Company notes added-matter standard used by EPO does not apply in US or other jurisdictions; no impact on other patent cases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184326000303/0001171843-26-000303-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184326000303/f8k_011626.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-000303

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer